Definitive Contract 75N93023C00034
Award Date
9/30/23
Potential Completion Date
9/29/25
Potential Value
$600K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Qrono, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Pittsburgh, PA 15213, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
10
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $597,598 firm fixed price definitive contract to Qrono Inc., located in Carson, Pennsylvania, to conduct research related to APC Specific MTOP Inhibition Potentiates Immune Response to IIV in Elderly Recipients. The contract is set aside as a total small business and will run from January 10, 2022 through January 9, 2024. Qrono Inc. will serve as the prime...
This federal contract award was made by the Food and Drug Administration (FDA), a civilian agency, to Qrono, Inc., a for-profit company specializing in medical and scientific research and development. The $694,584.58 cost-plus-fixed-fee contract, titled "Computational Drug Delivery: Leveraging Predictive Models to Develop Bioequivalent Generic Long-Acting Injections," is focused on developing innovative drug delivery systems and immunotherapy approaches. The contract has an ultimate...
This is a $599,234 firm fixed price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) to Celdara Medical, a small business biotechnology company, under the Small Business Innovation Research (SBIR) program. The contract is for research to discover parasite-derived tolerogenic adjuvants, which could potentially be used in new vaccine development. Celdara Medical conducts research and...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), awarded a $22,280.00 firm fixed price purchase order contract to Adaptive Biotechnologies Corporation (Adaptive) for immunosequencing services. The 1-year contract with a completion date of September 22, 2025 does not have a set-aside designation. Adaptive provides immune-driven medicine products and services, and has previously been awarded...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The $99,299 cost-plus-fixed-fee delivery order was placed under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase I clinical trials for therapeutic products targeting infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General Dynamics...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, awarded a $224,751 firm-fixed-price contract to Glucosentient Inc., a small business, for the development of a "TELE-MONITORING FOR INFECTIOUS DISEASES: A REMOTE SYSTEM FOR ASSESSING PATIENT PARAMETERS AND SPECIMEN ANALYSIS." The contract, which has an ultimate completion date of August 29, 2017, was set aside for small businesses. Glucosentient, a...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, awarded a firm-fixed-price purchase order contract for $14,887.50 to Parse Biosciences, Inc., a for-profit manufacturer of biotechnology products and services. The contract, which does not have a set-aside designation, is for the delivery of reagents to support single-cell RNA and T-cell receptor (TCR) sequencing of secondary hemophagocytic...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a firm-fixed price sole source contract to Adaptive Biotechnologies Corporation, a small business, for ImmunoSEQ hsTCRB v4 Service (Deep)-Academic RUO and DNA Extraction Service-immunoSEQ, with a ceiling value of $99,427.50. The contract is for specialized testing and genomic sequencing services that support NIAID's research programs. Adaptive Biotechnologies has a...
This is a $598,808 firm fixed price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Inimmune Corp. The contract is for research on adjuvant discovery for vaccines and for autoimmune and allergic diseases. Inimmune Corp is a biotechnology company with expertise in synthetic chemistry, drug formulation, and pharmaceutical manufacturing. They have received...
This is a $36,549,202.01 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the La Jolla Institute for Immunology, a non-profit research institute, for the Immune Epitope and Analysis Program. The contract has no set-aside designation and is set to run until December 14, 2025. As the prime contractor, the La Jolla Institute for Immunology is responsible for the overall program, which involves conducting research and providing services related to...